Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate Clostridium difficile Colitis while Dysregulating the Inflammatory Response.

Maseda D, Zackular JP, Trindade B, Kirk L, Roxas JL, Rogers LM, Washington MK, Du L, Koyama T, Viswanathan VK, Vedantam G, Schloss PD, Crofford LJ, Skaar EP, Aronoff DM.

MBio. 2019 Jan 8;10(1). pii: e02282-18. doi: 10.1128/mBio.02282-18.

2.

An Engineered Synthetic Biologic Protects Against Clostridium difficile Infection.

Vedantam G, Kochanowsky J, Lindsey J, Mallozzi M, Roxas JL, Adamson C, Anwar F, Clark A, Claus-Walker R, Mansoor A, McQuade R, Monasky RC, Ramamurthy S, Roxas B, Viswanathan VK.

Front Microbiol. 2018 Sep 5;9:2080. doi: 10.3389/fmicb.2018.02080. eCollection 2018.

3.

Epithelial maturity influences EPEC-induced desmosomal alterations.

Roxas JL, Vedantam G, Viswanathan VK.

Gut Microbes. 2018 Sep 5:1-5. doi: 10.1080/19490976.2018.1506669. [Epub ahead of print]

PMID:
30183504
4.

Enteropathogenic Escherichia coli EspH-Mediated Rho GTPase Inhibition Results in Desmosomal Perturbations.

Roxas JL, Monasky RC, Roxas BAP, Agellon AB, Mansoor A, Kaper JB, Vedantam G, Viswanathan VK.

Cell Mol Gastroenterol Hepatol. 2018 Apr 27;6(2):163-180. doi: 10.1016/j.jcmgh.2018.04.007. eCollection 2018.

5.

Biofilm Structures in a Mono-Associated Mouse Model of Clostridium difficile Infection.

Soavelomandroso AP, Gaudin F, Hoys S, Nicolas V, Vedantam G, Janoir C, Bouttier S.

Front Microbiol. 2017 Oct 25;8:2086. doi: 10.3389/fmicb.2017.02086. eCollection 2017.

6.

A Clostridium difficile Cell Wall Glycopolymer Locus Influences Bacterial Shape, Polysaccharide Production and Virulence.

Chu M, Mallozzi MJ, Roxas BP, Bertolo L, Monteiro MA, Agellon A, Viswanathan VK, Vedantam G.

PLoS Pathog. 2016 Oct 14;12(10):e1005946. doi: 10.1371/journal.ppat.1005946. eCollection 2016 Oct.

7.

Characterisation of Clostridium difficile strains isolated from Groote Schuur Hospital, Cape Town, South Africa.

Kullin B, Brock T, Rajabally N, Anwar F, Vedantam G, Reid S, Abratt V.

Eur J Clin Microbiol Infect Dis. 2016 Oct;35(10):1709-18. doi: 10.1007/s10096-016-2717-6. Epub 2016 Jul 27.

PMID:
27465145
8.

The Clostridium difficile Protease Cwp84 Modulates both Biofilm Formation and Cell-Surface Properties.

Pantaléon V, Soavelomandroso AP, Bouttier S, Briandet R, Roxas B, Chu M, Collignon A, Janoir C, Vedantam G, Candela T.

PLoS One. 2015 Apr 29;10(4):e0124971. doi: 10.1371/journal.pone.0124971. eCollection 2015.

9.

The secreted effector protein EspZ is essential for virulence of rabbit enteropathogenic Escherichia coli.

Wilbur JS, Byrd W, Ramamurthy S, Ledvina HE, Khirfan K, Riggs MW, Boedeker EC, Vedantam G, Viswanathan VK.

Infect Immun. 2015 Mar;83(3):1139-49. doi: 10.1128/IAI.02876-14. Epub 2015 Jan 5.

10.

Enteropathogenic Escherichia coli dynamically regulates EGFR signaling in intestinal epithelial cells.

Roxas JL, Ryan K, Vedantam G, Viswanathan VK.

Am J Physiol Gastrointest Liver Physiol. 2014 Aug 1;307(3):G374-80. doi: 10.1152/ajpgi.00312.2013. Epub 2014 Jun 5.

11.

Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostridium difficile.

Merrigan MM, Venugopal A, Roxas JL, Anwar F, Mallozzi MJ, Roxas BA, Gerding DN, Viswanathan VK, Vedantam G.

PLoS One. 2013 Nov 12;8(11):e78404. doi: 10.1371/journal.pone.0078404. eCollection 2013.

12.

Carbohydrate-based Clostridium difficile vaccines.

Monteiro MA, Ma Z, Bertolo L, Jiao Y, Arroyo L, Hodgins D, Mallozzi M, Vedantam G, Sagermann M, Sundsmo J, Chow H.

Expert Rev Vaccines. 2013 Apr;12(4):421-31. doi: 10.1586/erv.13.9. Review.

PMID:
23560922
13.

Clostridium difficile clinical isolates exhibit variable susceptibility and proteome alterations upon exposure to mammalian cationic antimicrobial peptides.

McQuade R, Roxas B, Viswanathan VK, Vedantam G.

Anaerobe. 2012 Dec;18(6):614-20. doi: 10.1016/j.anaerobe.2012.09.004. Epub 2012 Sep 24.

PMID:
23017940
14.

Spirochaetes and their twisted ways.

Vedantam G, Viswanathan VK.

Gut Microbes. 2012 Sep-Oct;3(5):399-400. Epub 2012 Sep 1. Review.

PMID:
22976336
15.

The enteropathogenic Escherichia coli-secreted protein EspZ inhibits host cell apoptosis.

Roxas JL, Wilbur JS, Zhang X, Martinez G, Vedantam G, Viswanathan VK.

Infect Immun. 2012 Nov;80(11):3850-7. doi: 10.1128/IAI.00335-12. Epub 2012 Aug 20.

16.

Naming names: eponyms and biological history.

Vedantam G, Viswanathan VK.

Gut Microbes. 2012 May-Jun;3(3):173-5. doi: 10.4161/gmic.20454. Epub 2012 May 1.

17.

Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response.

Vedantam G, Clark A, Chu M, McQuade R, Mallozzi M, Viswanathan VK.

Gut Microbes. 2012 Mar-Apr;3(2):121-34. doi: 10.4161/gmic.19399. Epub 2012 Mar 1. Review.

18.

Clostridium difficile carbohydrates: glucan in spores, PSII common antigen in cells, immunogenicity of PSII in swine and synthesis of a dual C. difficile-ETEC conjugate vaccine.

Bertolo L, Boncheff AG, Ma Z, Chen YH, Wakeford T, Friendship RM, Rosseau J, Weese JS, Chu M, Mallozzi M, Vedantam G, Monteiro MA.

Carbohydr Res. 2012 Jun 1;354:79-86. doi: 10.1016/j.carres.2012.03.032. Epub 2012 Apr 2.

PMID:
22533919
19.

Mobile genetic elements in the genus Bacteroides, and their mechanism(s) of dissemination.

Nguyen M, Vedantam G.

Mob Genet Elements. 2011 Sep;1(3):187-196. Epub 2011 Sep 1.

20.

Leptin signaling protects the gut from Entamoeba histolytica infection.

Vedantam G, Viswanathan VK.

Gut Microbes. 2012 Jan-Feb;3(1):2-3. doi: 10.4161/gmic.19424. Epub 2012 Jan 1. Review.

PMID:
22356851
21.

Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization.

Siddiqui F, O'Connor JR, Nagaro K, Cheknis A, Sambol SP, Vedantam G, Gerding DN, Johnson S.

J Infect Dis. 2012 Jan 1;205(1):128-33. doi: 10.1093/infdis/jir688. Epub 2011 Nov 28.

PMID:
22124129
22.

Unlocking the gates to inflammatory bowel disease: the role of Enterococcus faecalis gelatinase.

Vedantam G, Viswanathan VK.

Gastroenterology. 2011 Sep;141(3):795-8. doi: 10.1053/j.gastro.2011.07.022. Epub 2011 Jul 23. No abstract available.

PMID:
21791208
23.

A more perfect union.

Vedantam G, Viswanathan VK.

Gut Microbes. 2011 May-Jun;2(3):125-6. Epub 2011 May 1. No abstract available.

PMID:
21637032
24.

Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions.

Viswanathan VK, Mallozzi MJ, Vedantam G.

Gut Microbes. 2010 Jul;1(4):234-242. Epub 2010 Jun 16.

25.

Clostridium perfringens alpha toxin is produced in the intestines of broiler chicks inoculated with an alpha toxin mutant.

Coursodon CF, Trinh HT, Mallozzi M, Vedantam G, Glock RD, Songer JG.

Anaerobe. 2010 Dec;16(6):614-7. doi: 10.1016/j.anaerobe.2010.09.006. Epub 2010 Oct 8.

PMID:
20934524
26.

Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.

Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S, Gerding DN, Vedantam G.

J Bacteriol. 2010 Oct;192(19):4904-11. doi: 10.1128/JB.00445-10. Epub 2010 Jul 30.

27.

Spore-forming Bacilli and Clostridia in human disease.

Mallozzi M, Viswanathan VK, Vedantam G.

Future Microbiol. 2010 Jul;5(7):1109-23. doi: 10.2217/fmb.10.60. Review.

PMID:
20632809
28.

Identification of novel pathogenicity loci in Clostridium perfringens strains that cause avian necrotic enteritis.

Lepp D, Roxas B, Parreira VR, Marri PR, Rosey EL, Gong J, Songer JG, Vedantam G, Prescott JF.

PLoS One. 2010 May 24;5(5):e10795. doi: 10.1371/journal.pone.0010795. Erratum in: PLoS One. 2010;5(6). doi: 10.1371/annotation/501e5656-71ac-420f-a194-80141f6381e5.

29.

Antimicrobial resistance in Bacteroides spp.: occurrence and dissemination.

Vedantam G.

Future Microbiol. 2009 May;4(4):413-23. doi: 10.2217/fmb.09.12. Review.

PMID:
19416011
30.

Toxin B is essential for virulence of Clostridium difficile.

Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI.

Nature. 2009 Apr 30;458(7242):1176-9. doi: 10.1038/nature07822. Epub 2009 Mar 1.

31.

Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.

O'Connor JR, Galang MA, Sambol SP, Hecht DW, Vedantam G, Gerding DN, Johnson S.

Antimicrob Agents Chemother. 2008 Aug;52(8):2813-7. doi: 10.1128/AAC.00342-08. Epub 2008 Jun 16.

32.

Deciphering Evolutionary Mechanisms Between Mutualistic and Pathogenic Symbioses.

Nishiguchi MK, Hirsch AM, Devinney R, Vedantam G, Riley MA, Mansky LM.

Vie Milieu Paris. 2008;58(2):87-106.

33.

Characterization of BctA, a mating apparatus protein required for transfer of the Bacteroides fragilis conjugal element BTF-37.

Hecht DW, Kos IM, Knopf SE, Vedantam G.

Res Microbiol. 2007 Sep;158(7):600-7. Epub 2007 Jul 13.

PMID:
17720457
35.

Antibiotics and anaerobes of gut origin.

Vedantam G, Hecht DW.

Curr Opin Microbiol. 2003 Oct;6(5):457-61. Review.

PMID:
14572537
38.

The Bacteroides fragilis BtgA mobilization protein binds to the oriT region of pBFTM10.

Sitailo LA, Zagariya AM, Arnold PJ, Vedantam G, Hecht DW.

J Bacteriol. 1998 Sep;180(18):4922-8.

39.
40.

Characterization of mutations contributing to sulfathiazole resistance in Escherichia coli.

Vedantam G, Guay GG, Austria NE, Doktor SZ, Nichols BP.

Antimicrob Agents Chemother. 1998 Jan;42(1):88-93.

Supplemental Content

Loading ...
Support Center